Larimar Therapeutics, Inc.
About Larimar Therapeutics, Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2019
- $0
- Net income
- -$165.7M
- Total assets
- $145.8M
- Market cap
- $329.3M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $172.5M
- Operating income
- -$172.5M
- Income tax
- $0
- Net income
- -$165.7M
Balance sheet
- Total assets
- $145.8M
- Current assets
- $142.0M
- Total liabilities
- $67.8M
- Current liabilities
- $64.8M
- Shareholders’ equity
- $78.1M
Cash flow
- Operating cash flow
- -$113.2M
- Investing cash flow
- $100.3M
- Financing cash flow
- $65.1M
- Net cash flow
- $52.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $329.3M
- Shares outstanding
- 106.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 29, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $165.7M in FY2019.
- Trading 48% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Larimar Therapeutics, Inc..
Write a review
News about Larimar Therapeutics, Inc.
News & sentiment via Polygon.io
